Literature DB >> 22447156

Effects of bisphosphonates on osteoclastogenesis in RAW264.7 cells.

Keigo Abe1, Yoshitaka Yoshimura, Yoshiaki Deyama, Takashi Kikuiri, Tomokazu Hasegawa, Kanchu Tei, Hisashi Shinoda, Kuniaki Suzuki, Yoshimasa Kitagawa.   

Abstract

Bisphosphonates are used as therapeutic agents for the management of osteoporosis and other bone diseases. However, the precise effects and mechanisms of bisphosphonates on osteoclastogenesis are unclear, as previous studies have reported contradictory findings and no studies have circumstantially assessed the effects of bisphosphonates on osteoclastogenesis. Therefore, the aim of this study was to determine the effects of bisphosphonates on osteoclastogenesis in RAW264.7 (RAW) cells. To examine the direct effects of bisphosphonates on osteoclast differentiation via receptor activator of nuclear factor-κB (RANK) ligand (RANKL), RAW cells were cultured with bisphosphonates. Addition of bisphosphonates to RAW cells led to a significant decrease in the number of osteoclasts and large osteoclasts (≥ 8 nuclei) in a bisphosphonate concentration-dependent and time-dependent manner. The cytotoxicity of non-nitrogen-containing bisphosphonates was specific to osteoclasts, while nitrogen-containing bisphosphonates were cytotoxic and induced cell death in both osteoclasts and RAW cells. Resorption activity was significantly diminished by treatment with bisphosphonates, thus confirming that bisphosphonates impair the absorptive activity of osteoclasts. We also investigated the effects of bisphosphonates on the mRNA expression of genes associated with osteoclastogenesis, osteoclast-specific markers and apoptosis-related genes using quantitative real-time PCR. The results suggest that bisphosphonates suppress osteoclast differentiation and infusion, and induce osteoclast apoptosis. With regard to osteoclast apoptosis induced by bisphosphonates, we further investigated the detection of DNA fragmentation and Caspase-Glo 3/7 assay. DNA fragmentation was confirmed after treatment with bisphosphonates, while caspase-3/7 activity increased significantly when compared with controls. In conclusion, bisphosphonates directly inhibited RANKL-stimulated osteoclast differentiation and fusion in RAW cells. It was confirmed that bisphosphonates impair osteoclast resorption activity and induce apoptosis. The effects of non-nitrogen-containing bisphosphonates were also specific to osteoclasts, while nitrogen-containing bisphosphonates were cytotoxic and induced cell death in both osteoclasts and RAW cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22447156     DOI: 10.3892/ijmm.2012.952

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  9 in total

1.  Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function.

Authors:  Ranya Elsayed; Pheba Abraham; Mohamed E Awad; Zoya Kurago; Balasudha Baladhandayutham; Gary M Whitford; David H Pashley; Charles E McKenna; Mohammed E Elsalanty
Journal:  Bone       Date:  2018-02-09       Impact factor: 4.398

2.  Effects of cyclic tension stress on the apoptosis of osteoclasts in vitro.

Authors:  Fengbo Li; Xiaolei Sun; Bin Zhao; Jianxiong Ma; Yang Zhang; Shuang Li; Yanjun Li; Xinlong Ma
Journal:  Exp Ther Med       Date:  2015-03-09       Impact factor: 2.447

Review 3.  RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects.

Authors:  Pan-Feng Wu; Ju-yu Tang; Kang-hua Li
Journal:  Tumour Biol       Date:  2015-01-25

4.  Cell cytoskeleton and proliferation study for the RANKL-induced RAW264.7 differentiation.

Authors:  Lingbo Kong; Rui Ma; Yang Cao; Wanli Smith; Yuan Liu; Xiaobin Yang; Liang Yan
Journal:  J Cell Mol Med       Date:  2021-03-19       Impact factor: 5.310

5.  Tartrate-resistant acid phosphatase 5b is a marker of osteoclast number and volume in RAW 264.7 cells treated with receptor-activated nuclear κB ligand.

Authors:  Yuandong Lv; Guihua Wang; Weihong Xu; Pinghua Tao; Xiaoling Lv; Yazhen Wang
Journal:  Exp Ther Med       Date:  2014-11-14       Impact factor: 2.447

6.  Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways.

Authors:  Xiao-Lin Huang; Lie-Yu Huang; Yu-Ting Cheng; Fang Li; Qian Zhou; Chao Wu; Qian-Hui Shi; Zhi-Zhong Guan; Jian Liao; Wei Hong
Journal:  Int J Mol Med       Date:  2019-05-23       Impact factor: 4.101

7.  Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression.

Authors:  Wei Lin; Xing-Fu Li; Dong-Cheng Ren; Meng Song; Li Duan; Jin-Zhu Liu; Zi-Rui Zhan
Journal:  Mol Med       Date:  2021-02-26       Impact factor: 6.354

8.  Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation.

Authors:  Masanobu Tsubaki; Makiko Komai; Tatsuki Itoh; Motohiro Imano; Kotaro Sakamoto; Hirotaka Shimaoka; Tomoya Takeda; Naoki Ogawa; Kenji Mashimo; Daiichiro Fujiwara; Junji Mukai; Katsuhiko Sakaguchi; Takao Satou; Shozo Nishida
Journal:  J Biomed Sci       Date:  2014-02-03       Impact factor: 8.410

9.  4-Acetylantroquinonol B Inhibits Osteoclastogenesis by Inhibiting the Autophagy Pathway in a Simulated Microgravity Model.

Authors:  Chia-Hsin Wu; Ching-Huei Ou; I-Chuan Yen; Shih-Yu Lee
Journal:  Int J Mol Sci       Date:  2020-09-22       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.